Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PRKDC_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PRKDC_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PRKDC_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PRKDC_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PRKDC_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRKDC_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PRKDC_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PRKDC_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRKDC_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00102124 | Lung | IAC | response to ionizing radiation | 31/2061 | 148/18723 | 3.07e-04 | 4.89e-03 | 31 |
GO:19019902 | Lung | IAC | regulation of mitotic cell cycle phase transition | 53/2061 | 299/18723 | 3.14e-04 | 4.98e-03 | 53 |
GO:00315703 | Lung | IAC | DNA integrity checkpoint | 27/2061 | 123/18723 | 3.34e-04 | 5.24e-03 | 27 |
GO:00086307 | Lung | IAC | intrinsic apoptotic signaling pathway in response to DNA damage | 23/2061 | 99/18723 | 3.83e-04 | 5.87e-03 | 23 |
GO:00075693 | Lung | IAC | cell aging | 28/2061 | 132/18723 | 4.73e-04 | 6.92e-03 | 28 |
GO:2000134 | Lung | IAC | negative regulation of G1/S transition of mitotic cell cycle | 20/2061 | 84/18723 | 6.42e-04 | 8.74e-03 | 20 |
GO:00421106 | Lung | IAC | T cell activation | 77/2061 | 487/18723 | 6.82e-04 | 9.20e-03 | 77 |
GO:20000452 | Lung | IAC | regulation of G1/S transition of mitotic cell cycle | 29/2061 | 142/18723 | 7.27e-04 | 9.60e-03 | 29 |
GO:00000752 | Lung | IAC | cell cycle checkpoint | 33/2061 | 169/18723 | 7.51e-04 | 9.82e-03 | 33 |
GO:00457278 | Lung | IAC | positive regulation of translation | 28/2061 | 136/18723 | 7.79e-04 | 1.01e-02 | 28 |
GO:00488633 | Lung | IAC | stem cell differentiation | 38/2061 | 206/18723 | 9.79e-04 | 1.18e-02 | 38 |
GO:1902807 | Lung | IAC | negative regulation of cell cycle G1/S phase transition | 21/2061 | 93/18723 | 9.98e-04 | 1.19e-02 | 21 |
GO:00456466 | Lung | IAC | regulation of erythrocyte differentiation | 13/2061 | 47/18723 | 1.29e-03 | 1.45e-02 | 13 |
GO:19028061 | Lung | IAC | regulation of cell cycle G1/S phase transition | 32/2061 | 168/18723 | 1.38e-03 | 1.53e-02 | 32 |
GO:00070932 | Lung | IAC | mitotic cell cycle checkpoint | 26/2061 | 129/18723 | 1.62e-03 | 1.71e-02 | 26 |
GO:00487328 | Lung | IAC | gland development | 68/2061 | 436/18723 | 1.94e-03 | 1.97e-02 | 68 |
GO:19019911 | Lung | IAC | negative regulation of mitotic cell cycle phase transition | 33/2061 | 179/18723 | 2.05e-03 | 2.05e-02 | 33 |
GO:00506735 | Lung | IAC | epithelial cell proliferation | 68/2061 | 437/18723 | 2.05e-03 | 2.05e-02 | 68 |
GO:19031311 | Lung | IAC | mononuclear cell differentiation | 66/2061 | 426/18723 | 2.63e-03 | 2.44e-02 | 66 |
GO:00107698 | Lung | IAC | regulation of cell morphogenesis involved in differentiation | 20/2061 | 96/18723 | 3.58e-03 | 3.00e-02 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKDC | SNV | Missense_Mutation | | c.1855G>C | p.Asp619His | p.D619H | P78527 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
PRKDC | SNV | Missense_Mutation | novel | c.3658N>G | p.Leu1220Val | p.L1220V | P78527 | protein_coding | deleterious(0.01) | possibly_damaging(0.622) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
PRKDC | SNV | Missense_Mutation | novel | c.1504N>A | p.Glu502Lys | p.E502K | P78527 | protein_coding | tolerated(0.18) | benign(0.076) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
PRKDC | SNV | Missense_Mutation | novel | c.5396N>G | p.Glu1799Gly | p.E1799G | P78527 | protein_coding | tolerated(0.13) | benign(0.118) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PRKDC | SNV | Missense_Mutation | | c.9458C>G | p.Ser3153Cys | p.S3153C | P78527 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
PRKDC | SNV | Missense_Mutation | novel | c.5745N>C | p.Leu1915Phe | p.L1915F | P78527 | protein_coding | deleterious(0) | probably_damaging(0.914) | TCGA-A7-A6VV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
PRKDC | SNV | Missense_Mutation | | c.2706A>T | p.Lys902Asn | p.K902N | P78527 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
PRKDC | SNV | Missense_Mutation | | c.2210N>T | p.Pro737Leu | p.P737L | P78527 | protein_coding | deleterious(0.01) | benign(0.354) | TCGA-A8-A099-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD |
PRKDC | SNV | Missense_Mutation | | c.6367N>T | p.Pro2123Ser | p.P2123S | P78527 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PRKDC | SNV | Missense_Mutation | | c.3394N>A | p.Asp1132Asn | p.D1132N | P78527 | protein_coding | tolerated(0.21) | benign(0.055) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 252827496 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | | M9831 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | | KU-0060648 | CHEMBL1086377 | 23855836 |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 178102582 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565693 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 354702239 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 178102681 | WORTMANNIN | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | | SF1126 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565692 | | |
5591 | PRKDC | TRANSCRIPTION FACTOR COMPLEX, SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, PHOSPHATIDYLINOSITOL 3 KINASE, CLINICALLY ACTIONABLE | inhibitor | 404859048 | | |